Compare SILC & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SILC | TTRX |
|---|---|---|
| Founded | 1987 | 2015 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 263.8M | 298.8M |
| IPO Year | 2002 | 2025 |
| Metric | SILC | TTRX |
|---|---|---|
| Price | $40.24 | $10.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | ★ 147.7K | 135.5K |
| Earning Date | 10-29-2026 | 11-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $52.16 | N/A |
| Revenue Next Year | $19.99 | $900.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.34 | $2.57 |
| 52 Week High | $63.00 | $16.45 |
| Indicator | SILC | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 34.92 | 41.09 |
| Support Level | $38.00 | $9.02 |
| Resistance Level | $49.51 | $11.04 |
| Average True Range (ATR) | 3.84 | 1.11 |
| MACD | -2.06 | -0.33 |
| Stochastic Oscillator | 3.48 | 5.84 |
Silicom Ltd is engaged in designing, manufacturing, marketing, and supporting high-performance networking and data infrastructure solutions for a broad range of servers, server-based systems, and communications devices. Its product categories consist of Server Adapters, Edge Networking Solutions, Switches, Edge AI Solutions, Edge Networking Accessories, 4G 5G Products, FPGA-Based Cards, and Others. Its geographic areas are the USA, North America - other, Israel, Europe, and Asia-Pacific. It derives a majority of its revenue from the USA.
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.